Exuma Biotechnology

Focus: Exuma Biotechnology is a China-based biotech company focused on CAR-T cell therapy development, currently in early-stage clinical development with one Phase 1 program.

Cell Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Exuma Biotechnology

AI assessmentNot Hiring

No open roles listed right now. Follow Exuma Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

C402-CD19-CAR

Diffuse Large B-cell-lymphoma

PHASE_1

Clinical Trials (1)

NCT06830031Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Phase 1

Help build intelligence for Exuma Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on cutting-edge CAR-T technology in a growing therapeutic area with significant unmet need in hematologic malignancies
Position at a public company provides potential equity upside and established governance structure versus earlier-stage private firms
China-based location offers access to large patient populations and rapidly expanding biotech ecosystem in Asia

Watch Out For

Company has zero active job openings, indicating either fully staffed state or potential hiring freeze
Very early pipeline with only one Phase 1 program creates extended timeline to clinical validation and revenue generation
Minimal public visibility: no publications, recent news, or financial data available limits assessment of scientific credibility and company health

Generated by Claude from Exuma Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline